Stock NTLA INTELLIA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
23.27 USD +3.42% Intraday chart for Intellia Therapeutics, Inc. +16.23% -23.68%
04-15 Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer CI
03-25 Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
Intellia Therapeutics Q4 Loss Widens
Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Intellia Therapeutics, ReCode to Develop Therapies For Cystic Fibrosis
Intellia Therapeutics, Inc. and ReCode Therapeutics Announces Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
Intellia Therapeutics Says Investigational Hereditary Angioedema Treatment Shows Promise in Phase 1 Study
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
Intellia Therapeutics Insider Sold Shares Worth $566,310, According to a Recent SEC Filing
Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees
Intellia Therapeutics Files Mixed Shelf
Intellia Therapeutics Receives EU Orphan Drug Designation for Hereditary Angioedema Candidate Therapy
Intellia Therapeutics Shares Fall After Net Loss Narrows, but Revenue Falls in Q3
Intellia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Intellia Therapeutics Says Its Protein Disorder Treatment Candidate Showed Consistent Reduction of Plasma Protein in Phase 1 Trial
Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting
Intellia Therapeutics Says Application for Investigational Transthyretin Amyloidosis Treatment Cleared by FDA
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NTLA Stock
  4. News Intellia Therapeutics, Inc.
  5. Other languages